{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:00:38Z","timestamp":1783004438451,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.eururo.2015.12.048","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T05:41:46Z","timestamp":1453441306000},"page":"124-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia"],"prefix":"10.1016","volume":"70","author":[{"given":"Mauro","family":"Gacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Erik","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Oelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Porst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.12.048_bib0300","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.eururo.2011.06.037","article-title":"Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"60","author":"Gacci","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0305","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","article-title":"A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with \u03b1-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"61","author":"Gacci","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bju.12728","article-title":"Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis","volume":"115","author":"Gacci","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.12.048_bib0315","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1743-6109.2007.00498.x","article-title":"A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction","volume":"4","author":"Corona","year":"2007","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0320","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pros.22686","article-title":"PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS","volume":"73","author":"Vignozzi","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2015.12.048_bib0325","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/pros.22584","article-title":"Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit","volume":"73","author":"Morelli","year":"2013","journal-title":"Prostate"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2015.12.048_bib0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2003.09.030","article-title":"Storage and voiding symptoms: pathophysiologic aspects","volume":"62","author":"Andersson","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0335","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2008.03.109","article-title":"Lower urinary tract symptoms revisited: a broader clinical perspective","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0340","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.eururo.2009.07.044","article-title":"A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature","volume":"56","author":"Roosen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0345","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0022-5347(17)54139-7","article-title":"The etiology of detrusor hyperreflexia in patients with infravesical obstruction","volume":"127","author":"Chalfin","year":"1982","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0350","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.juro.2009.12.060","article-title":"Bladder afferent signaling: recent findings","volume":"183","author":"Kanai","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0355","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14728222.2015.1009447","article-title":"Therapeutic targets for overactive bladder other than smooth muscle","volume":"19","author":"Michel","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.eururo.2015.12.048_bib0360","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4161\/org.25895","article-title":"The concept of peripheral modulation of bladder sensation","volume":"9","author":"Eastham","year":"2013","journal-title":"Organogenesis"},{"key":"10.1016\/j.eururo.2015.12.048_bib0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cne.20785","article-title":"Micturition and the soul","volume":"493","author":"Holstege","year":"2005","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0370","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/iju.12288","article-title":"Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly","volume":"21","author":"Sakakibara","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0375","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1210\/en.2006-1079","article-title":"Characterization and functional role of androgen-dependent PDE5 activity in the bladder","volume":"148","author":"Filippi","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0380","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1743-6109.2009.01511.x","article-title":"Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract","volume":"7","author":"Fibbi","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0385","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1111\/j.1743-6109.2012.02946.x","article-title":"Testosterone\/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors","volume":"9","author":"Vignozzi","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0390","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1111\/j.1743-6109.2011.02416.x","article-title":"Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats","volume":"8","author":"Morelli","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0395","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2015.01.050","article-title":"Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension\/emptying and abdominal aorta clamping\/release","volume":"754","author":"Yoshinaga","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0400","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/nau.22732","article-title":"Effects of the phosphodiesterase 5 inhibitor tadalafil on bladder function in a rat model of partial bladder outlet obstruction","volume":"35","author":"Kawai","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2015.12.048_bib0405","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1743-6109.2009.01558.x","article-title":"Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats","volume":"7","author":"Morelli","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0410","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1743-6109.2009.01249.x","article-title":"Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA\/Rho kinase signaling pathway in spontaneously hypertensive rats","volume":"6","author":"Morelli","year":"2009","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0415","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/jsm.12478","article-title":"Tadalafil effect on metabolic syndrome-associated bladder alterations: an experimental study in a rabbit model","volume":"11","author":"Vignozzi","year":"2014","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0420","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s11547-009-0449-8","article-title":"Effect of Tadalafil on prostate hemodynamics: preliminary evaluation with contrast-enhanced US","volume":"114","author":"Bertolotto","year":"2009","journal-title":"Radiol Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0425","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.urology.2014.02.063","article-title":"Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial","volume":"84","author":"Pinggera","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0430","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.urology.2007.10.051","article-title":"Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue","volume":"71","author":"Uckert","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0435","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1476-5381.2010.00748.x","article-title":"Signaling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle","volume":"160","author":"Oger","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0440","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/j.1743-6109.2012.02821.x","article-title":"Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck","volume":"9","author":"Angulo","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0445","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1464-410X.2006.06501.x","article-title":"Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms","volume":"98","author":"Tinel","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.12.048_bib0450","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/nau.22528","article-title":"Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model","volume":"34","author":"Maciejewski","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2015.12.048_bib0455","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1210\/en.2012-1431","article-title":"Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation","volume":"153","author":"Zenzmaier","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0460","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/en.2009-1411","article-title":"Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia","volume":"151","author":"Zenzmaier","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0470","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/pros.22909","article-title":"Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia","volume":"75","author":"Zarifpour","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2015.12.048_bib0475","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0090-4295(94)80206-8","article-title":"Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses","volume":"44","author":"Ehr\u00e9n","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0480","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.eururo.2010.07.026","article-title":"Nitric oxide\/cyclic guanosine monophosphate signaling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat","volume":"58","author":"Caremel","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0485","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.juro.2007.07.048","article-title":"Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study","volume":"178","author":"Gacci","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0490","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1464-410X.2010.09698.x","article-title":"Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review","volume":"107","author":"Laydner","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.12.048_bib0495","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.urology.2010.07.508","article-title":"Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"77","author":"Liu","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0500","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/jsm.12499","article-title":"The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"11","author":"Yan","year":"2014","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0505","doi-asserted-by":"crossref","first-page":"e107593","DOI":"10.1371\/journal.pone.0107593","article-title":"Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: A systematic review and network meta-analysis","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2015.12.048_bib0510","first-page":"99","article-title":"The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction","volume":"5","author":"Gacci","year":"2013","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0515","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000351405","article-title":"Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis","volume":"91","author":"Dong","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2015.12.048_bib0520","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1756287214531639","article-title":"A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction","volume":"6","author":"Hatzimouratidis","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0525","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the Benign Prostatic Hyperplasia Impact Index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0530","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.juro.2014.11.094","volume":"193","author":"Oelke","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0535","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.12926","article-title":"Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"115","author":"Nickel","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.12.048_bib0540","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00345-014-1374-6","article-title":"Nocturia and its impact on health related quality of life and health care seeking behavior in German community-dwelling men aged 50 years or older","volume":"32","author":"Oelke","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0545","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00345-014-1255-z","article-title":"Effects of tadalafil on night-time voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: analyses of pooled data from four randomized, placebo-controlled clinical studies","volume":"32","author":"Oelke","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0550","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/jsm.12212","volume":"10","author":"Porst","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0555","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.juro.2013.09.057","article-title":"Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies","volume":"191","author":"Brock","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0560","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.urology.2013.05.005","article-title":"Efficacy and safety of tadalafil 5mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies","volume":"82","author":"Porst","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2015.12.048_bib0565","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/iju.12699","article-title":"Tadalafil 5mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies","volume":"22","author":"Nishizawa","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0570","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/ijcp.12722","volume":"69","author":"Vlachopoulos","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2015.12.048_bib0575","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.juro.2013.10.074","article-title":"Effects of tadalafil once-daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"191","author":"Roehrborn","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.12.048_bib0580","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jsm.12357","article-title":"A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"11","author":"Singh","year":"2014","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0585","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jsm.12714","article-title":"Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride","volume":"12","author":"Glina","year":"2015","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2015.12.048_bib0590","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jsm.12039","volume":"10","author":"Giuliano","year":"2013","journal-title":"J Sex Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T01:57:06Z","timestamp":1537063026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0302283816000063"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.12.048","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.12.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}